Characteristics and findings of all studies included (n = 72).

In the column “Short-term response SOT” is the number of patients given that had a positive response >2 weeks and ≤3 months after the last vaccination while in the column “Long-term response SOT” the number of patients that kept a positive response after ≥12 months is given (exceptions are marked with number). Data presented as number of patients with vaccination response/total number of patients.Design: pu - prospective uncontrolled, pc - prospective controlled, r- retrospective, ra – randomized, c-case report Patients: A - adult, P – paediatric, HTX- heart transplantation, RTX - renal transplantation, LTX – liver transplantation, PTX- lung transplantation, ITX – intestinal transplantation, ESRD- end stage renal disease Response: SOT – solid organ transplant recipient, HC - healthy control group, Vaccine, Vaccination schedule: T – tetanus toxoid vaccine, d – diphtheria vaccine (adult formulation with reduced antigen amount), D - diphtheria vaccine (paediatric formulation with higher antigen amount), IPV – inactivated polio vaccine, HAV – hepatitis A vaccine, rHBV - recombinant hepatitis B vaccine, TIV - trivalent inactivated influenza vaccine, PPV23- 23-valent pneumococcal vaccine, PCV7- seven-valent pneumococcal conjugate vaccine, HibV – Haemophilus influenzae vaccine, TBEV - tick borne encephalitis vaccine, MMR – mumps, measles, rubella vaccine, RVV – rabies virus vaccine, VZVV – varicella zoster vaccine, MMRV – mumps, measles, rubella, varicella vaccine, NA - not applicable.1patients receiving a chimeric monoclonal antibody against CD20.2patients receiving conventional immunosuppressive medication.3after 1st dose, controls received a different vaccination scheme compared to SOT recipients (one vs. two doses of vaccine, respectively).4after 2nd dose, controls received a different vaccination scheme compared to SOT recipients (one vs. two doses of vaccine, respectively).5after 3rd dose, controls received a different vaccination scheme compared to SOT recipients (one vs. two doses of vaccine, respectively).6patients were randomized to vaccine vs. no vaccine for the purpose of studying rejection.7patients receiving calcineurin-inhibitors.8patients receiving sirolimus.9patients receiving mycophenolate mofetil.10patients receiving azathioprin.11SOT recipients received either one or two doses of vaccine, however data for the double-dose trial are not given and stated that no difference to the single dose trial.12subunit vaccine.13virosomal vaccine.14for controls exact numbers were not given but stated that no difference between patients and controls.15response measured by enzyme-linked immunoassay (ELISA).16response measured by opsophagonization assay (OPA).17response measured by enzyme-linked immunoassay (ELISA).18response measured by opsophagonization assay (OPA).19long-term response of PPV 23 vs. PCV7 by follow up of the cohort by Kumar et al. 2003, mean continued response from patients initially vaccinated against PPV23 from varying patient numbers of ranging from 2 to 10 patients.20long-term response of PPV 23 vs. PCV7 by follow up of the cohort by Kumar et al. 2003, mean continued response of patients initially vaccinated against PCV7 from varying patient numbers ranging from 4 to 11 patients.21mean response after PCV7 only to serotypes 4, 6B, 9V, 14, 18C, 19F, 23F.22mean response after PCV7 followed by PPV23 to serotype 1, 5 und 7F after additional PP23 vaccination in the cohort from 23.23response to measles component.24response to mumps component.25response to rubella component.26response to mumps component.27response to measles component.28response to rubella component.29long-term response was accepted as 6 months after vaccination.30adequate response was seen but which decreased rapidly.